ADMA Biologics Inc
NASDAQ:ADMA
ADMA Biologics Inc
Revenue
ADMA Biologics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADMA Biologics Inc
NASDAQ:ADMA
|
Revenue
$258.2m
|
CAGR 3-Years
83%
|
CAGR 5-Years
72%
|
CAGR 10-Years
56%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
ADMA Biologics Inc
Revenue Breakdown
Breakdown by Geography
ADMA Biologics Inc
Total Revenue:
258.2m
USD
|
United States:
244.9m
USD
|
International:
13.3m
USD
|
Breakdown by Segments
ADMA Biologics Inc
See Also
What is ADMA Biologics Inc's Revenue?
Revenue
258.2m
USD
Based on the financial report for Dec 31, 2023, ADMA Biologics Inc's Revenue amounts to 258.2m USD.
What is ADMA Biologics Inc's Revenue growth rate?
Revenue CAGR 10Y
56%
Over the last year, the Revenue growth was 68%. The average annual Revenue growth rates for ADMA Biologics Inc have been 83% over the past three years , 72% over the past five years , and 56% over the past ten years .